Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis

IgA Vasculitis Clinical Trial

— RIGA  

Official title:

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05329090
• Other study ID #: 2019_0068
• Status: Recruiting
• Phase: Phase 3
• Start date: March 11, 2022
• Est. completion date: March 11, 2026

Study information

• Verified date: June 2024
• Source: Hopital Foch
• Contact: Romain Paule, Dr
• Phone: 33 1 46 25 25 76
• Email: r.paule[@]hopital-foch.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Systemic vasculitis are inflammatory diseases of the blood vessels, responsible for systemic manifestations. Among the systemic vasculitis affecting small blood vessels, IgA vasculitis (IgAV) is one of the most common forms and mainly affects the skin, joints, kidneys and gastrointestinal tract. Kidney and gastrointestinal damage can be serious, causing complications and life-threatening sequelae, especially in adults. The treatment of adult-onset IgAV is still a matter of debate. Glucocorticoids have been the standard of care for inducing remission for years in severe forms of IgAV. However, not all patients achieve remission and may experience disease flares associated with increased morbidity and mortality. In addition, the cumulative side effects of glucocorticoids are also major causes of long-term adverse events and death.Rituximab (RTX), an anti-CD20 monoclonal antibody, has been shown to be spectacularly effective in inducing remission in d 'other small vascular vessels, in particular ANCA-associated vasculitis and cryoglobulinemic vasculitis, with an acceptable safety profile.

Recently, a multicenter observational study suggested that RTX was an effective and safe therapeutic option for treating relapsed and / or refractory adult IgAV.

Overall, RTX may be an effective and safe therapeutic approach in adult IgAVs, justifying the need for a prospective randomized controlled trial evaluating Rituximab as an induction of remission for adult IgAV.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: March 11, 2026
• Est. primary completion date: March 11, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Biopsy-proven diagnosis of IgAV according to Chapel Hill Consensus Conference definitions

• Patient aged of 18 years or older

• Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an active disease defined by active manifestations attributable to IgAV

• Patients with severe involvement of at least one organ

• Patients within the first 21 days following initiation/increase of glucocorticoids at a dose < 1 mg/kg/day

• Has signed an informed consent form prior to any study related procedures

• Affiliated to a national health insurance

Exclusion Criteria:

• Patients with ANCA-associated vasculitis, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,

• Patients with IgAV in remission of the disease,

• Patients with severe cardiac failure defined as class IV in New York Heart Association,

• Patients with severe, uncontrolled cardiac disease,

• Patients with acute infections or chronic active infections (including HIV, HBV or HCV),

• Patients with active cancer or recent malignancy (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment,

• Pregnant women and breastfeeding. Patients with childbearing potential must use reliable contraceptive methods throughout the study and at least for 12 months after the last study drug administration,

• Patients with IgAV who have already been treated with rituximab within the previous 12 months,

• Patients treated with immunosuppressive therapy within the last 3 months,

• Patients with hypersensitivity to human or chimeric monoclonal antibodies,

• Patients with contraindication to use rituximab,

• Patients treated with any concomitant drugs contraindicated for use with the rituximab according to its SmPC,

• Patients with contraindication to use routine care treatments (Glucocorticoids, Angiotensin-converting-enzyme (ACEis) or angiotensin receptor blockers (ARBs), dexchlorphéniramine),

• Patients in a severely immunocompromised state,

• Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric disorders, that could interfere with his/her compliance to protocol requirements,

• Patients currently participating in another clinical study or 3 months prior to randomization,

• Patients suspected not to be observant to the proposed treatments,

• Patients unable to give written informed consent prior to participation in the study

• Being deprived of liberty or under guardianship.

Related Conditions & MeSH terms

• IgA Vasculitis
• Vasculitis

Intervention

Drug:
• Rituximab Injection
anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients
• placebo
placebo experimental treatment

Locations

Country	Name	City	State
France	Hopital La Cavale Blanche	Brest
France	CHU Clermont Ferrand	Clermont-Ferrand
France	CHU Clermont Ferrand	Clermont-Ferrand
France	Hôpital Edouard Herriot	Lyon
France	APHM de La Timone	Marseille
France	CHU Marseille	Marseille
France	Hôpital André Grégoire	Montreuil
France	CHU Nantes	Nantes
France	CHU Nîmes (Caremeau)	Nîmes
France	Hôpital Cochin	Paris
France	CHU Strasbourg	Strasbourg
France	Hôpital Foch	Suresnes
France	CHU Toulouse	Toulouse
France	CHRU Bretonneau	Tours

Sponsors (2)

Lead Sponsor	Collaborator
Hopital Foch	Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rituximab efficacy	The proportion of patients alive who achieved remission with a prednisone dose of 0 mg/day at both days 180 and 360	360 days
Secondary	Rituximab efficacy delay	Proportion of patients in remission at different research times	360 days
Secondary	Rituximab efficacy delay	Proportion of patients with BVAS=0 (or BVAS of =5 if all scores were due to persistent hematuria or proteinuria) and a prednisone dose =5 mg/day at days 180 and 360	360 days
Secondary	IgAV relapses	Number of major and minor relapse at 12 months	180 days
Secondary	IgAV relapses	Cumulative incidence of relapse at 12 months	180 days
Secondary	IgAV relapses	Time to first IgAV relapse	180 days
Secondary	Number of participants with adverse events for the safety analyse	Adverse events, expressed as adverse events according to the CTCAE toxicity grading system per patient-year at days 180 and 360 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions, death	360 days
Secondary	The glucocorticoids dose	Prednisone dosage at days 180 and 360 in the two treatment groups	360 days
Secondary	The glucocorticoids dose	Area under the curve for prednisone dose at days 180 and 360 in the two treatment groups	360 days
Secondary	Number of patients with a complete or partial renal remission & renal outcome remission	Proportion of patients in complete renal and partial renal remission at days 180 and 360; - Renal parameters at days 180 and 360 compared with baseline	360 days
Secondary	Number of patients with a complete or partial renal remission & renal outcome remission	Renal parameters at days 180 and 360 compared with baseline	360 days
Secondary	The sequelae assessed by the Vasculitis Damage Index	The Vasculitis Damage Index at days 180 and 360 in the two treatment groups	360 days
Secondary	Patient survival and quality of life	Quality of life as measured by the HAQ and SF-36 questionnaires at days 180 and 360	360 days
Secondary	Patient survival and quality of life	The patient-reported outcomes (PRO) including patient-reported disease activity, anxiety and depression, burden of the disease and treatment and adherence to treatment, at days 180 and 360 after randomization in the two treatment groups, and during the long-term follow-up	360 days
Secondary	Patient survival and quality of life	Number of patient survival	360 days
Secondary	To assess renal outcome	A complete response is defined as a decrease in the proteinuria level to < 0.5 gm/ day (or urine protein-to-creatinine ratio <0.5 gm/gm), the disappearance of hematuria, and no decrease in the eGFR of more than 20% from baseline.	360 days